Apalutamide Prevents SARS-CoV-2 Infection in Lung Epithelial Cells and in Human Nasal Epithelial Cells
Majidipur et al.,
Apalutamide Prevents SARS-CoV-2 Infection in Lung Epithelial Cells and in Human Nasal Epithelial Cells,
International Journal of Molecular Sciences, doi:10.3390/ijms24043288 (In Vitro)
In Vitro study showing that TMPRSS2 expression is regulated by androgens in Calu-3 cells, and treatment with anti-androgen drugs such as apalutamide significantly reduced SARS-CoV-2 entry and infection in both Calu-3 lung cells and primary human nasal epithelial cells.
Majidipur et al., 7 Feb 2023, France, peer-reviewed, 20 authors.
Contact:
virginie.firlej@u-pec.fr (corresponding author).
In Vitro studies are an important part of preclinical research, however results may be very different in vivo.
Abstract: International Journal of
Molecular Sciences
Article
Apalutamide Prevents SARS-CoV-2 Infection in Lung Epithelial
Cells and in Human Nasal Epithelial Cells
Amene Majidipur 1 , Margot Morin-Dewaele 2, Jeanne Gaspar Lopes 1, Francois Berry 2, Julien Fouchet 1,
Sophie Bartier 3,4,5, Anais Dufros Duval 1, Pascale Soyeux 1, Eric Huet 1 , Bruno Louis 5, André Coste 3,4,5,
Émilie Béquignon 3,4,5 , Carolina Saldana 1,6, Philippe Le Corvoisier 7, Damien Destouches 1 ,
Jean-Michel Pawlotsky 2,8, Alexandre de la Taille 1,6,9, Francis Vacherot 1, Patrice Bruscella 2,† and Virginie Firlej 1,*,†
1
2
3
4
5
6
7
8
9
*
†
Citation: Majidipur, A.; MorinDewaele, M.; Gaspar Lopes, J.; Berry,
F.; Fouchet, J.; Bartier, S.; Dufros
Duval, A.; Soyeux, P.; Huet, E.; Louis,
B.; et al. Apalutamide Prevents
SARS-CoV-2 Infection in Lung
Epithelial Cells and in Human Nasal
Epithelial Cells. Int. J. Mol. Sci. 2023,
24, 3288. https://doi.org/10.3390/
ijms24043288
Academic Editor: Francesco B. Blasi
Received: 5 December 2022
TRePCa, Université Paris Est Créteil, F-94010 Créteil, France
Team “Viruses, Hepatology, Cancer”, Institut Mondor de Recherche Biomédicale, Université Paris Est Créteil,
INSERM U955, F-94010 Créteil, France
Department of ENT and Head and Neck Surgery, Centre Hospitalier Intercommunal de Créteil,
F-94010 Créteil, France
AP-HP, Department of ENT and Head and Neck Surgery, Centre Hospitalier Universitaire Henri Mondor,
F-94010 Créteil, France
Team “Biomechanics and Respiratory System“, Institut Mondor de Recherche Biomédicale,
Université Paris Est Créteil, INSERM U955, CNRS EMR 7000, F-94010 Créteil, France
AP-HP, Department of Oncology, Centre Hospitalier Universitaire Henri Mondor, F-94010 Créteil, France
INSERM, AP-HP, Clinical Investigation Center 1430, Henri Mondor University Hospital, F-94000 Créteil, France
AP-HP, Department of Virology, Centre Hospitalier Universitaire Henri Mondor, F-94010 Créteil, France
AP-HP, Department of Urology, Centre Hospitalier Universitaire Henri Mondor, F-94010 Créteil, France
Correspondence: virginie.firlej@u-pec.fr; Tel.: +33-1-49-81-36-14
These authors contributed equally to this work.
Abstract: In early 2020, the novel pathogenic severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) emerged in Wuhan, China, and rapidly propagated worldwide causing a global health
emergency. SARS-CoV-2 binds to the angiotensin-converting enzyme 2 (ACE2) protein for cell entry,
followed by proteolytic cleavage of the Spike (S) protein by the transmembrane serine protease
2 (TMPRSS2), allowing fusion of the viral and cellular membranes. Interestingly, TMPRSS2 is a
key regulator in prostate cancer (PCa) progression which is regulated by androgen receptor (AR)
signaling. Our hypothesis is that the AR signaling may regulate the expression of TMPRSS2 in
human respiratory cells and thus influence the membrane fusion entry pathway of SARS-CoV-2.
We show here that TMPRSS2 and AR are expressed in Calu-3 lung cells. In this cell line, TMPRSS2
expression is regulated by androgens. Finally, pre-treatment with anti-androgen drugs such as
apalutamide significantly reduced SARS-CoV-2 entry and infection in Calu-3 lung cells but also in
primary human nasal epithelial cells. Altogether, these data provide strong evidence to support the
use of apalutamide as a treatment option for the PCa population vulnerable to severe COVID-19.
Keywords: SARS-CoV-2; androgen; ARPI; TMPRSS2
Revised: 29 January 2023
Accepted: 2 February..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit